Survival in Patients With Cryptogenic Fibrosing Alveolitis*

Size: px
Start display at page:

Download "Survival in Patients With Cryptogenic Fibrosing Alveolitis*"

Transcription

1 Survival in Patients With Cryptogenic Fibrosing Alveolitis* A Population-Based Cohort Study Richard Hubbard, DM; Ian johnston, MD; and john Britton, MD Study objectives: To determine the median survival of patients with cryptogenic fibrosing alveolitis, in comparison to that expected of individuals of the same age and sex from the general population. To estimate the effect of survival bias incurred by studying both incident and prevalent cases. To identify factors associated with survival. Design: Cohort study. Setting: Nine hospitals from the Trent Region of England. Patients: Two hundred forty-four cases of cryptogenic fibrosing alveolitis: 168 patients were alive on day 1 of the study (prevalent cases), and 76 patients had newly diagnosed conditions over a prospective 18-month period of patient recruitment (incident cases). Measurements: Age, sex, date of diagnosis, lung function at presentation, and details of treatment prescribed were extracted from hospital clinical records. Data on lifetime smoking habits were collected by postal questionnaire. Vital status was established from the general practitioner. The expected survival of each case was extracted from the English life tables. Results: Median survival for incident cases was 2.9 years and for prevalent cases 9 years, compared to expected values of 10 and 13 years, respectively. Incident cases had significantly worse survival than prevalent cases, even after adjustment for the effects of age, sex, smoking history, lung function at presentation, and treatment (hazard ratio, 4.53 [95% confidence interval, to 7.56]; p<0.001). Lower FVC at presentation and the use of corticosteroid treatment were both associated with worse survival. Conclusions: The inclusion of prevalent cases leads to significant overestimation of the median survival for patients with cryptogenic fibrosing alveoli tis. In newly diagnosed cases of cryptogenic fibrosing alveolitis, median survival is only 2.9 years, and expected life span is reduced by approximately 7 years. (CHEST 1998; 113: ) Key words: cryptogenic fibrosing a lveolitis; epidemiology; idiopathic pulmonary fibrosis ; survival Abbreviations: CI=confidence inte1val; HRCT = high-resolution CT; Tc o =transfer factor for carbon monoxide. cryptogenic fibrosing alveolitis is the most common of the interstitial lung diseases, with a prevalence in the United States of approximately 20/100,000.1 The registered mortality from cryptogenic fibrosing alveolitis is increasing progressively in a number of countries. 2 The median survival of patients with cryptogenic flbrosing alveolitis has been estimated from clinical case series to be approximately 5 y ears. 3-5 However, because these series included prevalent cases who by definition are survivors, these estimates of median survival may have been influenced by survival bias. Furthermore, because the cases included in these series were mainly collected at tertiary referral centers, they may be unrepresentative of the typical spectrum of disease. To estimate more accurately the prognosis of patients with cryptogenic fibrosing alveolitis and to estimate years of life lost in what is an elderly patient group, we have examined the survival of a population-based sample of prevalent and incident cases, and compared this to the expected survival in the general population. *From the University of N otingham, Division of Respiratory Medicine (Drs. Hubbard and Britton), City Hospital, and the Queens Respiratory Unit (Dr. Johnston), Queens Medical Centre, Nottingham, UK. Supported by the Medical Research Council. Manuscript received April 17, 1997; revision accepted July 14, MATERIALS AND METHODS The patients were identified as part of a case-control study o f occupational causes of cryptogenic fibrosing a lveolitis. Details of patient identi fication, data collection, and diagnostic criteria have been published elsewhere. 6 We attempted t o identify all patients

2 with cryptogenic fibrosing alveoli tis attending nine centers within the Trent Region of England at the outset of the study (the prevalent cases), and all new patients seen during an 18-month recruitment period (the incident cases), using all available lung function laboratory records, hospital discharge data, and local diagnostic registers. The hospital clinical records of each potential case were then inspected to ascertain those who fulfilled our diagnostic criteria, which are set out in Table 1 and which are similar to those used by other researchers. 3 7 Since it is usual clinical practice in the United Kingdom to obtain histologic confirmation of the diagnosis only in the minority of patients in whom the high-resolution CT (HRCT) and other clinical findings do not support a diagnosis of cryptogenic fibrosing alveolitis, 8 we did not make histologic confirmation mandatory to our diagnostic criteria. We defined date of diagnosis as the date on which the cases first met our diagnostic criteria. Six months after the end of patient recruitment, we established the survival status of each prevalent case from their general practitioner, and confirmed dates of deaths were possible with hospital records and local health authority records. Eighteen months after completion of patient recruitment, we repeated this process for the incident cases. We collected data on lifetime smoking habit by postal questionnaire as previously described, 6 and extracted details of lung function at presentation and treatments prescribed from hospital clinical records. We estimated median actuarial survival from diagnosis for incident and prevalent cases separately using a statistical package (EGRET; Statistics and Epidemiology Research Corp; Seattle, Wash; ). To provide a comparison with survival in the general population, we used data from the English life tables 10 that contain the expected future survival for each sex at each year of life. We extracted the expected survival of all patients, based on their age and sex, from the tables and calculated the median expected survival for this "control population," again using the statistical package (EGRET). We then compared the survival of incident cases with that of prevalent cases, and that of our control population, using Cox's proportional hazards survival analysis (EGRET). Finally we examined the effect of age at diagnosis, sex, histmy of every having been a smoker, FVC at presentation, transfer factor for carbon monoxide (Teo) at presentation, and use of treatment with corticosteroids, cyclophosphamide, or azathioprine on survival using Cox's proportional hazards survival analysis for incident and prevalent cases separately. RESULTS A total of 168 (105 male) prevalent cases and 76 (56 male) incident cases were identified. Open lung Table!-Diagnostic Criteria Criteria Histologic confirmation of diagnosis from an open lung biopsy specimen or all of the following: l. Basal inspiratory pulmonary crackles on examination 2. Bilateral interstitial lung shadowing on chest radiograph 3. No documented history of exposure to asbestos or other recognized fibrogens, including birds 4. No clinical evidence of coexisting collagen vascular disease 5. No other coexisting cause of interstitial lung disease 6. Restrictive lung function defined as FEV,IFVC>70% together with an FVC or Tco<80% of predicted; in the absence of restrictive lung function, patients were included if there were pathognomonic changes of cryptogenic fibrosing alveolitis on an HRCT scan biopsy was performed in 31 (12.7%) cases, and the mean age of these cases was significantly lower than those who did not have this procedure (52.4 years vs 69.0 years; p<o.ool). The proportion of prevalent cases who underwent open lung biopsy was higher than that for incident cases, but the opposite was true for HRCT (Table 2). Incident cases tended to be older, and were more likely to be male, and to report ever having been a smoker than prevalent cases (Table 2). Mean percent predicted FVC and Teo at presentation were similar for incident and prevalent cases, but the use of corticosteroids and immunosuppressive drugs was more common among prevalent cases. Median duration of follow-up from diagnosis was 3.6 years for prevalent cases, during which time 43 (26%) died, and 2.3 years for incident cases, during which time 39 (51%) died. The median actuarial survival for prevalent cases was 9.0 years, and for incident cases 2.9 years (Fig. 1). This compared to an expected median survival of 13 years for prevalent cases and 10 years for incident cases. Incident cases were significantly more likely to die than prevalent cases both before (hazard ratio, 3.69 [95% confidence interval (CI), 2.34 to 5.84]; p<o.ool) and after adjustment for the effects of age at diagnosis, sex, smoking, FVC, and Teo at presentation, steroid use, azathioprine use, and cyclophosphamide use (hazard ratio, 4.53 [CI, 2.71 to 7.56]; p<o.ool). Survival for incident cases was substantially worse than that expected for the general population (hazard ratio, [CI, 12.5 to 799.5]; p<o.ool). This increase in risk was much less marked for prevalent cases (hazard ratio, 6.21 [CI, 3.81 to 10.12]; p<o.ool). For incident cases, higher percent predicted FVC and Teo at presentation were associated with better survival, while steroid use and cyclophosphamide use were both associated with worse survival (Table 3). Survival was worse in men for each increasing year of age and for never smokers, but these effects were small and not significant at the 5% level. In contrast, for prevalent cases, age at diagnosis was significantly associated with survival (Table 3), and prognosis was worse in women, although not significantly so. Again, poorer lung function at presentation, never having been a smoker, and the use of treatment tended to be associated with worse survival, but only the effect of Teo was significant at the 5% level (Table 3). DISCUSSION In this study, we have shown that the median survival of newly diagnosed cases of cryptogenic fibrosing alveolitis is 2.9 years, and as such is not only substantially lower than that of prevalent cases, but also considerably worse than currently recognized. 3-5 CHEST I 113 I 2 I FEBRUARY,

3 Table 2-Details of Age, Sex, Smoking Habit, Lung Function at Presentation, and Treatment for Incident and Prevalent Cases* Incident Cases (n= 76) Prevalent Cases (n= 168) p Value Male :female 2.8:1 Mean (SD) age, yr, at presentation 69.7 (9.6) Ever smokers 1 58 ( n=65; 89%) Lung function at presentation: Mean (SE) percent predicted FVC 78.5 (2.8) Teo 49.2 (22) Open lung biopsy 5 (6.6%) HRCT 50 (65.8%) Treatment prescribed Corticosteroids 36 (47%) Cyclophosphamide 5 (6.8%) Azathioprine 2 (2.6%) *x 2 test used f or categorical data and unpaired t test for continuous data. 1 Different denominator as data from questionnaire. 1.7: (12.3) (n=145; 72%) (1.6) (1.4) (17.3%) (34.5%) < (65%) (11.9%) (131%) To establish our population of patients, we identified patients attending a range of secondary and tertiary referral centers within the Trent region of England, and thus believe that these cases are typical of patients presenting to respiratory and general physicians. To minimize survival and selection bias, we attempted to identify all cases attending these centers, and because we wanted to study survival in a general population-based sample of patients with disease diagnosed according to usual clinical practice, I,8 we did not make a histologic diagnosis an obligatory diagnostic criterion. Our diagnostic criteria were, however, more stringent than those used by others in epidemiologic studies.l In fact, in our study, 13% of patients underwent open lung biopsy, 0 0- l ~ ~ ~ - ~ 3 FIGURE l. Actuarial and expected survival for incident and prevalent cases. Y-axis=survival probability. X-axis = years. 1 =incident cases (circles represent censored data); 2=prevalent cases (triangles represent censored data); 3=expected survival for incident cases; and 4=expected survival for prevalent cases. and the mean age of this subgroup was significantly lower than that of cases who did not have an open lung biopsy, confirming that this group represent a selected subpopulation of patients who are not typical, at least in age, of patients with cryptogenic fibrosing alveolitis in the general population. The use of open lung biopsy was less common in incident cases compared to prevalent cases, while the use of HRCT was more common with two thirds of incident cases undergoing this investigation. The likely explanation for these findings is the general increasing reliance by physicians in many countries on HRCT as a diagnostic procedure since this technique is noninvasive, well tolerated by patients, and has a low false-positive rate for diagnosing cryptogenic fibrosing alveolitis. 13 The finding of a longer median survival in prevalent cases compared to incident cases is not unexpected, since the incident case group will contain the complete spectrum of newly diagnosed cases, while the prevalent group will exclude those who died quickly from aggressive disease (survival bias). The considerable difference in median survival between incident and prevalent cases demonstrates the strong effect of survival bias in this patient group. It seems likely that it is this effect of survival bias which is the explanation for the difference in median survival between our incident cases and previous estimates of median survival derived from mixtures of prevalent and incident cases accrued as part of clinical case series. 3-5 We believe, therefore, that our results represent a more accurate estimate of typical life expectancy of patients with newly diagnosed conditions which, at <3 years, is actually worse than that of patients with stage I non-small cell lung cancer. 14 Compared to their expected survival derived from the English life tables, our patients with newly 398

4 Table 3-The Effects of Sex, Age, Smoking History, Lung Function at Presentation, and Treatment on Survival* Incident Cases (n= 76) Prevalent Cases (n= 168) Odds Ratio (95% CI) p Value Odds ratio (95% CI) p Value Male sex 1.50 (0.77 to 2.93) (0.37 to 1.35) 0.29 Age 1.02 (0.98 to 1.06) (1.06 to 1.13) < Ever smoker 0.73 (0.28 to 1.88) (0.32 to 1.20) 0.16 FVC 0.98 (0.96 to 0.99) (0.98 to 1.00) 0.15 Teo 0.98 (0.96 to 0.99) (0.94 to 0.98) Steroids 2.01 (1.06 to 3.79) (0.96 to 4.51) Cyclophosphamide 5.05 (1.69 to 15.06) l. 79 (0. 79 to 4.04) 0.16 Azathioprine 2.39 (0.57 to 10.13) (0.37 to 2.38) 0.89 *Odds ratios are for men compared to women, for each additional year of life, ever smokers compared to never smokers, for each additional percent predkted FVC or TCO, and for treated compared to untreated. diagnosed cryptogenic fibrosing alveolitis have a much reduced survival with an average reduction in median life expectancy of approximately 7 years. One consequence of the marked effect of survival bias seen in this patient group is that when assessing the role of various factors on prognosis, ideally only data from incident cases should be used. The data from our incident cases demonstrate that although survival was worse in men, with each increasing year of age, these effects were small and not statistically significant. Previous studies have produced conflicting data with some finding positive effects for age3,5,l 5 or sex, 3 15 and others finding no effects for age 7 or sex Some of these previous studies 3 15 included a proportion of patients with connective tissue diseases, who tend to be younger, more often female, 17 and to have a better prognosis. 5.l 8 Inclusion of these patients will tend to bias the effects of age and sex on survival away from unity. The strong and significant effects of lung function at presentation on survival that we found have been repmted before Cigarette smoking has been identified recently as a risk factor for the development of cryptogenic fibrosing alveolitis, 6 11 and it is known to be associated with lower lung function in these patients. 20 However, we found no association between a history of ever having been a smoker and survival, and similar findings have been reported before A significant number of patients were not prescribed corticosteroids, and the fact that incident cases were treated less often than prevalent cases suggests that the decision to treat is often delayed for some time after diagnosis. This in turn probably reflects the paucity of data on the efficacy of treatments in this condition. In our study, patients who received treatment had a poorer survival than those who did not, and others have reported similar findings.16 The likely explanation for this is selection bias as physicians will tend to observe patients with stable or slowly progressive disease without initiating treatment, while patients thought to have deteriorating conditions with aggressive disease will tend to be given corticosteroids, azathioprine, or cyclophosphamide. The alternative explanation, that corticosteroids are detrimental to patients with cryptogenic fibrosing alveolitis, is less likely but cannot be excluded, because to our knowledge, there have been no controlled clinical trials of corticosteroids in this disease. In summary, unless only incident cases are included in estimates of survival in patients with cryptogenic fibrosing alveolitis, significant errors will occur because of survival bias. We estimate that median survival of patients with newly diagnosed cryptogenic fibrosing alveolitis is < 3 years and is considerably lower than previous reports. On average, the life span of patients with cryptogenic fibrosing alveolitis is reduced by 7 years. ACKNOWLEDGMENTS: The authors thank Dr. Sarah Firby (actuary) for statistical advice, the lung function technicians at the nine centers involved in this study for assisting with patient identification, and the consultant physicians who allowed us to approach their patients. We would also like to thank Nottinghamshire, Derbyshire, Leicestershire, Lincolnshire, and South Yorkshire Family Health Services Authorities for help with identification of control subjects, the General Practitioners, and the Medical Research Council who funded this study. REFERENCES 1 Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Grit Care Med 1994; 150: Hubbard R, Johnston I, Coultas DB, et a!. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996; 51: Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: Carrington CB, Gaensler EA, Coutu RE, et a!. Natural history and treated course of usual and desquamative interstitial pneumonia. N Eng! J Med 1978; 298: CHEST /113/2/ FEBRUARY,

5 5 Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Ct;t Care Med 1994; 149: Hubbard R, Lewis S, Richards K, e t al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996; 347: Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: Johnston IDA, Gomm SA, Kalra A, et al. The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom. Eur Respir J 1993; 6: Statistics and Epidemiology Research Corporation. Egret, reference manual. Seattle, Wash: SERC, Government Actuaty's Department. English life tables No th ed. London: HMSO, 1986; 1 11 Baumgartner KB, Samet JM, Stidly CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 155: Iwai K, Mori T, Yamada N, e t al. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994; 150: Tung KT, Wells AU, Rubens MR, et al. Accuracy of the typical computed tomographic appearances of fibrosing alveolitis. Thorax 1993; 48: Mountain CF. A new international staging system for lung cancer. Chest 1986; 89:225S-33S 15 Tukiainen P, Taskinen E, Holsti P, et al. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38: Coultas DB, Mapel Dlvl, Hunt C, et al. Idiopathic pulmonary fibrosis (IPF): survival in a population-based cohort. Am J Respir Crit Care Med 1996; 153:A Crystal RG, Fulmer CD, Roberts WC, et al. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85: Agusti C, Xaubet A, Roca J, et al. Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of 2-year follow-up. Thorax 1992; 47: Stack BHR, Choo-Kang YFJ, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972; 27: Schwartz DA, Merchant RK, Helmers RA, e t al. The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 144: de Cremoux H, Bernaudin JF, Laurent P, et al. Interactions between cigarette smoking and the natural history of idiopathic pulmonary fibrosis. Chest 1990; 98:

C aring for patients with interstitial lung disease is an

C aring for patients with interstitial lung disease is an 980 INTERSTITIAL LUNG DISEASE Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK J Gribbin, R B Hubbard, I Le Jeune, C J P Smith, J West, L J Tata... See end of article

More information

Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis

Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis Respiratory Medicine (2009) 103, 927e931 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic

More information

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis JULIE A. BJORAKER, JAY H. RYU, MARK K. EDWIN, JEFFREY L. MYERS, HENRY D. TAZELAAR, DARRELL R. SCHROEDER, and KENNETH

More information

Prognosis of cryptogenic fibrosing alveolitis

Prognosis of cryptogenic fibrosing alveolitis P TUKIAINEN, E TASKINEN, P HOLSTI, 0 KORHOLA, AND M VALLE Thorax 1983;38:349-355 From the Departments of Pulmonary Diseases, Oncology, and Diagnostic Radiology, University Central Hospital ofhelsinki,

More information

Cryptogenic fibrosing alveolitis and lung cancer: the BTS study

Cryptogenic fibrosing alveolitis and lung cancer: the BTS study 1 Occupational and Environmental Medicine, National Heart and Lung Institute, Imperial College, London, UK; 2 Nottingham University Hospitals, Queens Medical Centre Campus, Nottingham, UK; 3 London Lung

More information

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD) ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the

More information

ZOE D. DANIIL, FRANCES C. GILCHRIST, ANDREW G. NICHOLSON, DAVID M. HANSELL, JESSICA HARRIS, THOMAS V. COLBY, and ROLAND M. du BOIS

ZOE D. DANIIL, FRANCES C. GILCHRIST, ANDREW G. NICHOLSON, DAVID M. HANSELL, JESSICA HARRIS, THOMAS V. COLBY, and ROLAND M. du BOIS A Histologic Pattern of Nonspecific Interstitial Pneumonia Is Associated with a Better Prognosis Than Usual Interstitial Pneumonia in Patients with Cryptogenic Fibrosing Alveolitis ZOE D. DANIIL, FRANCES

More information

Venous thrombo-embolism in people with idiopathic pulmonary fibrosis: a population based study

Venous thrombo-embolism in people with idiopathic pulmonary fibrosis: a population based study Venous thrombo-embolism in people with idiopathic pulmonary fibrosis: a population based study Authors: William Dalleywater 1, Helen A Powell 1,,2, Andrew W Fogarty 1, Richard B Hubbard 1, Vidya Navaratnam

More information

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.

More information

Idiopathic pulmonary fibrosis (IPF), also referred to as

Idiopathic pulmonary fibrosis (IPF), also referred to as Operation for Lung Cancer in Patients With Idiopathic Pulmonary Fibrosis: Surgical Contraindication? Toshio Fujimoto, MD, Tsuyoshi Okazaki, MD, Tadashi Matsukura, MD, Takeshi Hanawa, MD, Naoki Yamashita,

More information

In idiopathic pulmonary fibrosis (IPF) and

In idiopathic pulmonary fibrosis (IPF) and Eur Respir J 2010; 35: 830 835 DOI: 10.1183/09031936.00155108 CopyrightßERS Journals Ltd 2010 Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

More information

Diffuse Interstitial Lung Diseases: Is There Really Anything New?

Diffuse Interstitial Lung Diseases: Is There Really Anything New? : Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There

More information

International consensus statement on idiopathic pulmonary fibrosis

International consensus statement on idiopathic pulmonary fibrosis Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic

More information

CTD-related Lung Disease

CTD-related Lung Disease 13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of

More information

prednisolone in combination in cryptogenic fibrosing

prednisolone in combination in cryptogenic fibrosing Thorax 1989;44:280-288 Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis M A JOHNSON, S KWAN, N

More information

Idiopathic pulmonary fibrosis (IPF) is a

Idiopathic pulmonary fibrosis (IPF) is a Eur Respir J 2011; 38: 176 183 DOI: 10.1183/09031936.00114010 CopyrightßERS 2011 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema S.L. Schmidt*,

More information

DIAGNOSTIC NOTE TEMPLATE

DIAGNOSTIC NOTE TEMPLATE DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the

More information

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,

More information

ANDREW G. NICHOLSON, THOMAS V. COLBY, ROLAND M. DUBOIS, DAVID M. HANSELL, and ATHOL U. WELLS

ANDREW G. NICHOLSON, THOMAS V. COLBY, ROLAND M. DUBOIS, DAVID M. HANSELL, and ATHOL U. WELLS The Prognostic Significance of the Histologic Pattern of Interstitial Pneumonia in Patients Presenting with the Clinical Entity of Cryptogenic Fibrosing Alveolitis ANDREW G. NICHOLSON, THOMAS V. COLBY,

More information

R etrospective studies on the natural history of fibrosing

R etrospective studies on the natural history of fibrosing 517 EXTENDED REPORT Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis J K Dawson, H E Fewins, J Desmond, M P Lynch, D R Graham... See end of article

More information

Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease

Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease Thorax 1999;54:1009 1014 1009 James Moon, Ronald M du Bois, Thomas V Colby, David M Hansell, Andrew G Nicholson Interstitial Lung Disease Unit J Moon R M du Bois Department of Radiology D M Hansell Department

More information

Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis

Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis Respiratory Medicine (2009) 103, 1209e1215 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary

More information

Outline Definition of Terms: Lexicon. Traction Bronchiectasis

Outline Definition of Terms: Lexicon. Traction Bronchiectasis HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of

More information

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients

More information

Common things are common, but not always the answer

Common things are common, but not always the answer Kevin Conroy, Joe Mackenzie, Stephen Cowie kevin.conroy@nhs.net Respiratory Dept, Darlington Memorial Hospital, Darlington, UK. Common things are common, but not always the answer Case report Cite as:

More information

Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation

Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation LUNG TRANSPLANTATION Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation Laura S Mackay, Rachel L Anderson, Gareth Parry, James Lordan, Paul A Corris, Andrew

More information

Access from the University of Nottingham repository:

Access from the University of Nottingham repository: Dallywater, William and Powell, Helen A. and Hubbard, Richard B. and Navaratnam, Vidya (2015) Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a population-based study.

More information

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial

More information

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose

More information

Liebow and Carrington's original classification of IIP

Liebow and Carrington's original classification of IIP Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans

More information

Occupational and Environmental Factors and Idiopathic Pulmonary Fibrosis in Japan

Occupational and Environmental Factors and Idiopathic Pulmonary Fibrosis in Japan Ann. occup. Hyg., Vol. 49, No. 3, pp. 259 265, 2005 # 2005 British Occupational Hygiene Society Published by Oxford University Press doi:10.1093/annhyg/meh090 Occupational and Environmental Factors and

More information

Incidence and prevalence of idiopathic pulmonary fibrosis in US adults years old

Incidence and prevalence of idiopathic pulmonary fibrosis in US adults years old ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASES Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18 64 years old Ganesh Raghu 1, Shih-Yin Chen 2, Qiang Hou 2, Wei-Shi Yeh 2 and Harold

More information

Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia

Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia Eur Respir J 2002; 19: 1114 1118 DOI: 10.1183/09031936.02.00244002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Survival of patients with

More information

Restrictive lung diseases

Restrictive lung diseases Restrictive lung diseases Restrictive lung diseases are diseases that affect the interstitium of the lung. Interstitium of the lung is the very thin walls surrounding the alveoli, it s formed of epithelium

More information

Cigarette Smoking and Lung Cancer

Cigarette Smoking and Lung Cancer Centers for Disease Control and Prevention Epidemiology Program Office Case Studies in Applied Epidemiology No. 731-703 Cigarette Smoking and Lung Cancer Learning Objectives After completing this case

More information

OFEV MEDIA BACKGROUNDER

OFEV MEDIA BACKGROUNDER OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small

More information

Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis A Randomized Prospective Study

Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis A Randomized Prospective Study Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis A Randomized Prospective Study WILLIAM W. DOUGLAS, JAY H. RYU, STEPHEN J. SWENSEN, KENNETH P. OFFORD, DARRELL R. SCHROEDER,

More information

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +

More information

Influence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern

Influence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern ORIGINAL ARTICLE Influence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern Tetsuro Sawata, Masashi Bando, Masayuki Nakayama, Naoko Mato, Hideaki Yamasawa

More information

Occupational and Environmental Risk Factors for Idiopathic Pulmonary Fibrosis in Egypt: A Multicenter Case-Control Study

Occupational and Environmental Risk Factors for Idiopathic Pulmonary Fibrosis in Egypt: A Multicenter Case-Control Study Original Article Occupational and Environmental Risk Factors for Idiopathic Pulmonary Fibrosis in Egypt: A Multicenter Case-Control Study NJ Awadalla 1, A Hegazy 2, RA Elmetwally 3, I Wahby 4 Abstract

More information

Differential diagnosis

Differential diagnosis Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential

More information

Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases

Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro

More information

INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf

INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly

More information

Progress in Idiopathic Pulmonary Fibrosis

Progress in Idiopathic Pulmonary Fibrosis Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim

More information

Lung cancer in idiopathic pulmonary fibrosis

Lung cancer in idiopathic pulmonary fibrosis Curr Respir Care Rep (2013) 2:248 253 DOI 10.1007/s13665-013-0060-2 INTERSTITIAL LUNG DISEASE (G TINO, SECTION EDITOR) Lung cancer in idiopathic pulmonary fibrosis Maryl Kreider Published online: 22 September

More information

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to

More information

Imaging: how to recognise idiopathic pulmonary fibrosis

Imaging: how to recognise idiopathic pulmonary fibrosis REVIEW IDIOPATHIC PULMONARY FIBROSIS Imaging: how to recognise idiopathic pulmonary fibrosis Anand Devaraj Affiliations: Dept of Radiology, St George s Hospital, London, UK. Correspondence: Anand Devaraj,

More information

Interstitial lung diseases and, in particular, idiopathic

Interstitial lung diseases and, in particular, idiopathic Assessment of Health-Related Quality of Life in Patients With Interstitial Lung Disease* Jacqueline A. Chang, MD; J. Randall Curtis, MD, MPH; Donald L. Patrick, PhD, MSPH; and Ganesh Raghu, MD, FCCP Study

More information

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University

More information

Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis

Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis JMAJ 46(11): 475 482, 2003 Kingo CHIDA Associate Professor, Second Division,

More information

Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone Results of a Prospective, Open-label Phase II Study

Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone Results of a Prospective, Open-label Phase II Study Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone Results of a Prospective, Open-label Phase II Study GANESH RAGHU, W. CRAIG JOHNSON, DIANE LOCKHART, and YOLANDA MAGETO

More information

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary

More information

ARTICLE IN PRESS. Ahuva Grubstein a, Daniele Bendayan b, Ithak Schactman c, Maya Cohen a, David Shitrit b, Mordechai R. Kramer b,

ARTICLE IN PRESS. Ahuva Grubstein a, Daniele Bendayan b, Ithak Schactman c, Maya Cohen a, David Shitrit b, Mordechai R. Kramer b, Respiratory Medicine (2005) 99, 948 954 Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature

More information

Capsaicin induced cough in cryptogenic fibrosing alveolitis

Capsaicin induced cough in cryptogenic fibrosing alveolitis 1028 Aintree Chest Centre and The University Department of Medicine, University Hospital Aintree, Liverpool, UK M J Doherty R Mister M G Pearson P M A Calverley Correspondence to: Professor P Calverley,

More information

The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis

The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis Respiratory Medicine (2005) 99, 755 761 The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis Spyros A. Papiris a,, Zoe D. Daniil a, Katerina

More information

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic

More information

Interstitial Lung Disease

Interstitial Lung Disease Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation

More information

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment

More information

PNEUMOCONIOSES DIAGNOSIS, DIFFERENTIAL DIAGNOSIS AND TREATMENT. Carlos Robalo Cordeiro

PNEUMOCONIOSES DIAGNOSIS, DIFFERENTIAL DIAGNOSIS AND TREATMENT. Carlos Robalo Cordeiro PNEUMOCONIOSES DIAGNOSIS, DIFFERENTIAL DIAGNOSIS AND TREATMENT Carlos Robalo Cordeiro carlos.crobalo@gmail.com Diagnosis 1 History of sufficient exposure to dust, in time and intensity/either occupational

More information

Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature

Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Eur Respir Rev 12; 21: 126, 355 361 DOI: 1.1183/95918.2512 CopyrightßERS 12 REVIEW Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Luba Nalysnyk*, Javier Cid-Ruzafa

More information

Epidemiology and classification of smoking related interstitial lung diseases

Epidemiology and classification of smoking related interstitial lung diseases Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207

More information

Conflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck

Conflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck Conflicts of Interest Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck The Idiopathic Interstitial Pneumonias Idiopathic pulmonary

More information

In search of a cause of cryptogenic fibrosing alveolitis (CFA) : one initiating factor or many?

In search of a cause of cryptogenic fibrosing alveolitis (CFA) : one initiating factor or many? Thorax 1998;53(Suppl 2):S3 S9 In search of a cause of cryptogenic fibrosing alveolitis (CFA) : one initiating factor or many? Margaret Turner-Warwick Emeritus Professor of Medicine, University of London,

More information

Experience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina

Experience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib

More information

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling

More information

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe

More information

IPF: Epidemiologia e stato dell arte

IPF: Epidemiologia e stato dell arte IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic

More information

Combined Pulmonary Fibrosis and Emphysema - A Case Series

Combined Pulmonary Fibrosis and Emphysema - A Case Series IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 1 Ver. III (January. 2017), PP 15-19 www.iosrjournals.org Combined Pulmonary Fibrosis and Emphysema

More information

USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS

USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS Brestas P., Vergadis V., Emmanouil E., Malagari K. 2 nd Dept of Radiology, University of Athens, Greece ABSTRACT

More information

Case 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar

Case 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open

More information

Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias

Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias Respiratory Medicine (2007) 101, 655 660 Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias Yon Ju Ryu a, Man Pyo Chung b,, Joungho Han c, Tae Sung Kim d, Kyung Soo Lee d, Eun-Mi Chun

More information

Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis

Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis Original Article Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis Xia Li 1, Chang Chen 2, Jinfu Xu 1, Jinming Liu 1, Xianghua

More information

Idiopathic pulmonary fibrosis (IPF) is the. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is the. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis Eur Respir J 2010; 36: 1067 1072 DOI: 10.1183/09031936.00152609 CopyrightßERS 2010 A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis O. Nishiyama*,", H. Taniguchi*,

More information

Scholars Journal of Medical Case Reports

Scholars Journal of Medical Case Reports Scholars Journal of Medical Case Reports Sch J Med Case Rep 2015; 3(9B):928-932 Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific Resources)

More information

Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?

Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen

More information

Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens

Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens Patient with IPF and no honeycombing on HRCT Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 76-year-old male patient presented with progressive exertional dyspnoea refractory

More information

Chronic Cough Due to Chronic Interstitial Pulmonary Diseases. ACCP Evidence-Based Clinical Practice Guidelines

Chronic Cough Due to Chronic Interstitial Pulmonary Diseases. ACCP Evidence-Based Clinical Practice Guidelines Chronic Cough Due to Chronic Interstitial Pulmonary Diseases ACCP Evidence-Based Clinical Practice Guidelines Kevin K. Brown, MD, FCCP Objectives: To review the role of chronic interstitial pulmonary disease

More information

PNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera

PNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e

More information

Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia

Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2013; 30; 103-112 Mattioli 1885 Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia

More information

CDC Division of Oral Health 2018 Update

CDC Division of Oral Health 2018 Update CDC Division of Oral Health 2018 Update Organization for Safety, Sepsis and Prevention (OSAP) Annual Meeting Friday, June 1, 2018 Michele Junger, DDS, MPH Dental Officer Objectives Discuss a recent report

More information

Hypersensitivity Pneumonitis (HP)

Hypersensitivity Pneumonitis (HP) Hypersensitivity Pneumonitis (HP) Information for patients and families UHN Read this handout to learn about: What hypersensitivity pneumonitis (HP) is Signs and symptoms How your doctor will know if you

More information

DRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)

DRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) Reference: NHS England A/14/X01 CHECK Information Reader Box (IRB) to be

More information

Diffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious

Diffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -

More information

Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study

Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2018;50(2):374-381 Original Article https://doi.org/10.4143/crt.2017.119 Open Access Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide

More information

DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?

DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS

More information

Definition, classification and epidemiology

Definition, classification and epidemiology Interstitial Lung Diseases Definition, classification and epidemiology Haluk Türktaş Professor of Pulmonary Medicine Gazi University Ankara Interstitial Lung Diseases Definition of ILD A diverse group

More information

Serial computed tomographic evaluation in desquamative interstitial pneumonia

Serial computed tomographic evaluation in desquamative interstitial pneumonia Thorax 1997;52:333 337 333 Serial computed tomographic evaluation in desquamative interstitial pneumonia Masanori Akira, Satoru Yamamoto, Hideki Hara, Mitsunori Sakatani, Einosuke Ueda Abstract a better

More information

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease Eur Respir J 2010; 35: 1322 1328 DOI: 10.1183/09031936.00092309 CopyrightßERS 2010 Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease E.J. Kim*, B.M. Elicker #, F.

More information

I diopathic pulmonary fibrosis (IPF) is the most common

I diopathic pulmonary fibrosis (IPF) is the most common 1091 INTERSTITIAL LUNG DISEASE Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia L Tiitto, R Bloigu, U Heiskanen, P Pääkkö, V

More information

Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients

Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients Brazilian Journal of Medical and Biological Research (2007) 40: 179-187 Quality of life in idiopathic pulmonary fibrosis ISSN 0100-879X 179 Comparison of two questionnaires which measure the health-related

More information

Comments to the U.S. Food and Drug Administration Regarding the Patient-Focused Drug Development Re: Docket No. FDA-2012-N-0967

Comments to the U.S. Food and Drug Administration Regarding the Patient-Focused Drug Development Re: Docket No. FDA-2012-N-0967 Comments to the U.S. Food and Drug Administration Regarding the Patient-Focused Drug Development Re: Docket No. FDA-2012-N-0967 The American Lung Association welcomes the opportunity to comment on the

More information

COPD Bronchiectasis Overlap Syndrome.

COPD Bronchiectasis Overlap Syndrome. COPD Bronchiectasis Overlap Syndrome. John R Hurst 1, J Stuart Elborn 2, and Anthony De Soyza 3 on Behalf of the BRONCH-UK Consortium (D Bilton, J Bradley, JS Brown, J Duckers, F Copeland, A Floto, J Foweraker,

More information

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study 36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E

More information

Key words: CT scanners; interstitial lung diseases; polymyositis-dermatomyositis; x-ray

Key words: CT scanners; interstitial lung diseases; polymyositis-dermatomyositis; x-ray Nonspecific Interstitial Pneumonia Associated With Polymyositis and Dermatomyositis* Serial High-Resolution CT Findings and Functional Correlation Hiroaki Arakawa, MD; Hidehiro Yamada, MD; Yasuyuki Kurihara,

More information

Reduced lung function in midlife and cognitive impairment in the elderly

Reduced lung function in midlife and cognitive impairment in the elderly Page 1 of 5 Reduced lung function in midlife and cognitive impairment in the elderly Giuseppe Verlato, M.D. Ph.D Department of Diagnostics and Public Health University of Verona Verona, Italy Mario Olivieri,

More information

Asbestosis as a precursor of asbestos related lung

Asbestosis as a precursor of asbestos related lung British Journal of Industrial Medicine 1991;48:229-233 Asbestosis as a precursor of asbestos related lung cancer: results of a prospective mortality study Janet M Hughes, Hans Weill Abstract A prospective

More information

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical

More information

Progression of native lung fibrosis in lung transplant recipients with idiopathic pulmonary fibrosis

Progression of native lung fibrosis in lung transplant recipients with idiopathic pulmonary fibrosis Respiratory Medicine (2010) 104, 426e433 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Progression of native lung fibrosis in lung transplant recipients with idiopathic

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)

More information